机器人辅助部分肾切除术与微创根治性肾切除术治疗临床T2a期肾肿块的倾向性评分匹配比较:ROSULA协作组研究
该多中心回顾性研究经倾向性评分匹配(2:1)比较了机器人辅助部分肾切除术(RAPN)与微创根治性肾切除术(MIS-RN)治疗临床T2a期肾肿块(cT2aRM)的疗效。结果显示两种手术在肿瘤学结局和并发症方面无显著差异,但RAPN在保留肾功能方面具有优势,表现为术后新发eGFR<45 mL/min/1.73 m2的比例更低。RAPN可考虑作为cT2aRM的一线选择。
要点
- RAPN与MIS-RN在cT2aRM中肿瘤学结局(DFS、OS)相似,并发症率无显著差异。
- RAPN术后新发eGFR<45 mL/min/1.73 m2的5年无事件率显著高于MIS-RN(91.6% vs 68.9%,P<0.001)。
- RAPN可考虑作为cT2aRM的一线手术选择。
核心结论
- RAPN治疗cT2aRM具有与MIS-RN相似的肿瘤学结局和并发症谱,同时提供更好的肾功能保护。
- RAPN可考虑作为cT2aRM的一线选择。
研究设计与样本
- 多中心回顾性倾向性评分匹配(PSM)比较研究,纳入cT2aN0M0肾肿块患者,按RN:PN=2:1匹配,匹配变量包括年龄、性别、BMI、ASA分级、临床肿瘤大小和R.E.N.A.L.评分。
- 共匹配648例患者(RAPN 216例,MIS-RN 432例)。
- 主要终点为无病生存期(DFS),次要终点包括总生存期(OS)、并发症率和新发eGFR<45 mL/min/1.73 m2。
主要发现
- 术中并发症(P=0.478)、Clavien-Dindo≥III级并发症(P=0.063)和再入院率(P=0.238)在两组间无显著差异。
- 多变量分析显示高ASA分级(HR 2.7,P=0.044)和肉瘤样分化(HR 5.3,P=0.001)与全因死亡率相关,手术方式与全因死亡率无关(P=0.601)。
- R.E.N.A.L.评分升高(HR 1.31,P=0.037)、高肿瘤分级(HR 2.5,P=0.043)和肉瘤样分化(HR 2.8,P=0.02)与复发相关,手术方式与复发无关(P=0.555)。
- 年龄增长(HR 1.1,P<0.001)和根治性肾切除术(HR 3.9,P<0.001)是新发eGFR<45 mL/min/1.73 m2的预测因素。
- 对pT2肾细胞癌,RAPN与MIS-RN的5年OS(76.3% vs 88.0%,P=0.221)和5年DFS(78.6% vs 85.3%,P=0.630)无显著差异;对pT3a期上调肾细胞癌,3年OS(P=0.351)和3年DFS(P=0.117)也无差异。
临床怎么用
- 对于临床T2a期肾肿块患者,RAPN可作为一线手术选择,在保证肿瘤学安全的同时更好地保护肾功能。
- 决策时应综合考虑患者年龄、ASA分级、肿瘤R.E.N.A.L.评分和病理特征(如肉瘤样分化)等预后因素。
局限性
- 回顾性研究设计,存在选择偏倚可能。
- 倾向性评分匹配仅控制已知混杂因素,无法排除未测量混杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare outcomes of minimally invasive radical nephrectomy (MIS-RN) and robot-assisted partial nephrectomy (RAPN) in clinical T2a renal mass (cT2aRM). PATIENTS AND METHODS: Retrospective, multicentre, propensity score-matched (PSM) comparison of RAPN and MIS-RN for cT2aRM (T2aN0M0). Cohorts were PSM for age, sex, body mass index, American Society of Anesthesiologists (ASA) class, clinical tumour size, and R.E.N.A.L. score using a 2:1 ratio for RN:PN. The primary outcome was disease-free survival (DFS). Secondary outcomes included overall survival (OS), complication rates, and de novo estimated glomerular filtration rate (eGFR) <45 mL/min/1.73 m2 . Multivariable (MVA) and Kaplan-Meier survival analyses (KMSA) were conducted. RESULTS: In all, 648 patients (216 RAPN/432 MIS-RN) were matched. There were no significant differences in intraoperative complications (P = 0.478), Clavien-Dindo Grade ≥III complications (P = 0.063), and re-admissions (P = 0.238). The MVA revealed high ASA class (hazard ratio [HR] 2.7, P = 0.044) and sarcomatoid (HR 5.3, P = 0.001), but not surgery type (P = 0.601) to be associated with all-cause mortality. Increasing R.E.N.A.L. score (HR 1.31, P = 0.037), high tumour grade (HR 2.5, P = 0.043), and sarcomatoid (HR 2.8, P = 0.02) were associated with recurrence, but not surgery (P = 0.555). Increasing age (HR 1.1, P < 0.001) and RN (HR 3.9, P < 0.001) were predictors of de novo eGFR of <45 mL/min/1.73 m2 . Comparing RAPN and MIS-RN, KMSA revealed no significant differences for 5-year OS (76.3% vs 88.0%, P = 0.221) and 5-year DFS (78.6% vs 85.3%, P = 0.630) for pT2 RCC, and no differences for 3-year OS (P = 0.351) and 3-year DFS (P = 0.117) for pT3a upstaged RCC. The 5-year freedom from de novo eGFR of <45 mL/min/1.73 m2 was 91.6% for RAPN vs 68.9% for MIS-RN (P < 0.001). CONCLUSIONS: RAPN had similar oncological outcomes and morbidity profile as MIS-RN, while conferring functional benefit. RAPN may be considered as a first-line option for cT2aRM.
引用
- Bradshaw AW, Autorino R, Simone G, et al. Robotic partial nephrectomy vs minimally invasive radical nephrectomy for clinical T2a renal mass: a propensity score-matched comparison from the ROSULA (Robotic Surgery for Large Renal Mass) Collaborative Group. BJU Int. 2020. PMID: 32232920. doi:10.1111/bju.15064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。